NCT05028855 Cerebral Autoregulation in Patients With Symptomatic Cerebral Atherosclerotic Stenosis
| NCT ID | NCT05028855 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Yi Yang |
| Condition | Cerebrovascular Stroke |
| Study Type | OBSERVATIONAL |
| Enrollment | 850 participants |
| Start Date | 2017-01-14 |
| Primary Completion | 2025-12-24 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 850 participants in total. It began in 2017-01-14 with a primary completion date of 2025-12-24.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
In this multi-center prospective observational study within a cohort of symptomatic cerebral atherosclerotic stenosis (sCAS) patients, 850 subjects were planed to be enrolled to explore the relationship between cerebral autoregulation (CA) and stroke recurrence, determine the threshold values of CA parameter for predicting stroke recurrence associated with particular stenosis.
Eligibility Criteria
Inclusion Criteria: * Age ranging from 18 to 80, both genders * Unilateral internal carotid artery (ICA) or M1 segment of middle cerebral artery (MCA) stenosis (rate of stenosis ranging from 50-99%) * Acute ischemic cerebrovascular events (TIA or ischemic stroke) within cerebral stenotic artery supplying area * Onset of disease \<30 d before enrollment * Modified Ranking Scale (mRS) ≤1 before stroke onset * National Institutes of Health Stroke Scale (NIHSS) ≤20 * Sufficient bilateral temporal bone windows for insonation of the middle cerebral artery * Be conscious, and able to cooperate with CA assessment * Willing to participate and sign the informed consent Exclusion Criteria: * Vertebral artery (VA), basilar artery (BA), anterior cerebral artery (ACA), or posterior cerebral artery (PCA) stenosis; Bilateral internal carotid artery (ICA) or M1 segment of middle cerebral artery (MCA) stenosis(rate of stenosis ranging from 50-99%) * Patients who have received or plan to undergo intravascular interventional treatment/endarterectomy * Other intracranial diseases, including cerebral hemorrhage (primary or secondary), intracranial neoplasm, aneurysm, arteriovenous malformation, etc. * Evidence for embolic stroke, such as atrial fibrillation, prosthetic valve surgery, and suspected endocarditis, etc. * Arrhythmia, anemia and hyperthyroidism which may influence the stability of cerebral blood flow diagnosed by two physicians by electrocardiogram and laboratory tests. * Dementia, severe anxiety, depression, and other mental diseases * Malignant neoplasm and expected lifetime \<2 years * Enrolled in other clinical trails within 6 months
Contact & Investigator
Yi Yang, MD, PhD
STUDY CHAIR
Neuroscience Center, Department of Neurology, The First Hospital of Jilin University
Frequently Asked Questions
Who can join the NCT05028855 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 80 Years, studying Cerebrovascular Stroke. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05028855 currently recruiting?
Yes, NCT05028855 is actively recruiting participants. Contact the research team at doctor_yangyi@163.com for enrollment information.
Where is the NCT05028855 trial being conducted?
This trial is being conducted at Changchun, China.
Who is sponsoring the NCT05028855 clinical trial?
NCT05028855 is sponsored by Yi Yang. The principal investigator is Yi Yang, MD, PhD at Neuroscience Center, Department of Neurology, The First Hospital of Jilin University. The trial plans to enroll 850 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.